Focused On-demand Library for Prolyl 3-hydroxylase 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8IVL5

UPID:

P3H2_HUMAN

Alternative names:

Leprecan-like protein 1; Myxoid liposarcoma-associated protein 4

Alternative UPACC:

Q8IVL5; B3KPK0; B3KWI9; D3DNV8; Q9NVI2

Background:

Prolyl 3-hydroxylase 2, also known as Leprecan-like protein 1 or Myxoid liposarcoma-associated protein 4, plays a crucial role in collagen synthesis. It specifically catalyzes the post-translational formation of 3-hydroxyproline in collagens, essential for maintaining the structural integrity of tendons, the eye sclera, and the eye lens capsule. This enzyme exhibits high activity with type IV collagen COL4A1 and lower activity with COL1A1, crucial for tissue strength and resilience.

Therapeutic significance:

Given its pivotal role in collagen synthesis, Prolyl 3-hydroxylase 2 is directly linked to 'Myopia, high, with cataract and vitreoretinal degeneration', a disorder characterized by severe myopia, cataract, and vitreoretinal degeneration. Understanding the role of Prolyl 3-hydroxylase 2 could open doors to potential therapeutic strategies for treating or managing this complex disorder.